Business Development

Topotarget's strategy is focused on accelerated development and commercialization of belinostat in Europe and in the US. The promising product pipeline is built through a combination of in-house basic research, strategic acquisitions, and in-licensing.

Topotarget has a strong track record of successfully managing alliances with major pharmaceutical companies, biotech companies, and academic institutions, and will continue to do so in order to develop a portfolio of oncology product candidates balanced between specialty drugs and products with broader commercial potential.

Topotarget will capitalize on its skills in drug discovery and clinical development to move forward drug candidates into clinical development. For products with major market potential, Topotarget will seek partnerships with larger pharmaceutical companies to complete clinical development, regulatory approval, and commercialization.

For more information on the above opportunities please contact:


VP Business Development & Licensing/Strategic Planning
Topotarget A/S
Symbion Science Park
Fruebjergvej 3
DK-2100 Copenhagen
+45 39 17 83 92 (phone)
+45 39 17 94 92 (fax)
enquiries@topotarget.com (email)